A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

NEW YORK — (AP) — Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

DEAR DR. ROACH: I am a 52-year-old woman who was diagnosed with familial hypercholesterolemia in October 2024. I went through a cardiac workup for pain in my left arm and found this out.

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

Although Wegovy (semaglutide) is often used as a weight-loss medicine, it is well-known to be protective for the heart. Similarly, telmisartan is in the class of drugs that protect the heart, even in ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Viking Therapeutics' weight-loss pill trial results underwhelmed, causing a sharp decline in shares. Meanwhile, Novo Nordisk's liver disease approval for Wegovy uplifted its stock. European corporate ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Wegovy is now positioned as the first and only GLP-1 treatment.